EUVIMEDEUVIMED entdecken
Crossref

Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells

Shogo Ozawa

Innovative Medicines & Omics · 16.03.2026 · 3 (4) · 025520080

DOI: 10.36922/imo025520080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Medicines & Omics, online erschienen am 16.03.2026. Verfasst von Shogo Ozawa.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer stem cells (CSCs) express specific antigens associated with stemness. CSCs derived from solid tumors are resistant to various anticancer agents. Given that the spectrum of drug resistance in CSCs is not well understood, literature searches using various keyword combinations were performed to investigate whether CSCs residing in solid cancers are innately resistant to both lipophilic (e.g., P-glycoprotein substrates) and hydrophilic (e.g., non-P-glycoprotein substrates) substances. Current literature suggests that solid CSCs are more likely to acquire multidrug resistance; that is, they are significantly more likely to resist a wide variety of low-molecular-weight anticancer drugs regardless of whether these drugs are P-glycoprotein substrates. The present review further delineates emerging evidence on the use of nanomedicine to eradicate CSCs.

Zitieren

APA

Ozawa, S. (2026). Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells. Innovative Medicines & Omics, 3(4), 025520080. https://doi.org/10.36922/imo025520080

Vancouver

Ozawa S. Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells. Innovative Medicines & Omics. 2026;3(4):025520080. doi:10.36922/imo025520080

BibTeX
@article{Ozawa2026,
  author = {Ozawa, Shogo},
  title = {Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells},
  journal = {Innovative Medicines & Omics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {025520080},
  doi = {10.36922/imo025520080}
}
Kostenlos starten →